|
Market Closed -
Nasdaq
23:00:00 28/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 232.40 USD | +2.47% |
|
+3.24% | -41.56% |
| 10-26 | Alnylam Pharmaceuticals, Inc. - Special Call | |
| 10-23 | Alnylam Pharmaceuticals Reports 60% to 64% Huntingtin Reduction in Brezosiran Trial | MT |
| Market Cap | 31.1B 27.9B 25.8B 23.36B 43.65B 2,962B 44.17B 308B 123B 1,550B 117B 114B 4,920B | P/E 2026 * |
35x | P/E 2027 * | 24.1x |
|---|---|---|---|---|---|
| Enterprise Value | 28.11B 25.22B 23.31B 21.12B 39.45B 2,677B 39.93B 279B 111B 1,401B 105B 103B 4,447B | EV / Sales 2026 * |
5.13x | EV / Sales 2027 * | 3.81x |
| Free-Float |
99.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ALNY | Delayed | |
CBOE
| ALNY | Real-time | |
|
London S.E.
| 0HD2 | Delayed | |
|
Deutsche Boerse AG
| DUL | Delayed | |
|
Tradegate
| DUL | Real-time | |
|
Xetra
| DUL | End-of-day quote | |
|
Berne S.E.
| DUL | End-of-day quote | |
|
Boerse Muenchen
| DUL | Real-time | |
|
Börse Stuttgart
| DUL | Delayed | |
|
Borsa Italiana
| 1ALNY | End-of-day quote | |
|
Wiener Boerse
| ALNY | End-of-day quote |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | +2.47% | ||
| 1 week | +3.24% | ||
| Current month | -5.81% | ||
| 1 month | -8.99% | ||
| 3 months | -19.42% | ||
| 6 months | -23.07% | ||
| Current year | -41.56% |
| 1 week | 220 |  | 232.88 |
| 1 month | 215.46 | | 254.44 |
| Current year | 197.81 | | 427.05 |
| 1 year | 197.81 | | 479.79 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/01/2022 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 58 | 13/08/2019 |
| Chief Tech/Sci/R&D Officer | - | 01/04/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 80 | 23/04/2012 |
Amy Schulman
CHM | Chairman | 65 | 05/01/2023 |
David Pyott
BRD | Director/Board Member | 72 | 18/12/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/2/26 A | Sell | General Counsel | -1,758 | 0.0013% | ||
| 9/19/26 A | Free | Chief Executive Officer | 107 | 0.0001% | ||
| 6/1/26 A | Exercice | Director | 11,490 | 0.0086% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.47% | +3.24% | -51.17% | +53.14% | 30.35B | |
| +0.50% | +1.38% | +57.09% | +129.96% | 1,143B | |
| +0.86% | +5.14% | +45.00% | +86.15% | 647B | |
| -0.14% | +0.42% | +25.69% | +105.85% | 506B | |
| -0.05% | +1.73% | +52.74% | +67.74% | 384B | |
| -0.63% | -5.97% | +61.93% | +37.06% | 350B | |
| +0.34% | +1.84% | +30.70% | +54.27% | 293B | |
| -0.45% | +1.19% | +2.89% | +26.08% | 265B | |
| +0.87% | +3.08% | +54.69% | +72.74% | 242B | |
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | |
| Average | +0.38% | +1.63% | +31.46% | +74.08% | 405.79B | |
| Weighted average by Cap. | +0.27% | +1.56% | +43.78% | +88.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.48B 4.92B 4.55B 4.12B 7.69B 522B 7.78B 54.34B 21.65B 273B 20.56B 20.13B 867B | 6.92B 6.21B 5.74B 5.2B 9.71B 659B 9.83B 68.64B 27.34B 345B 25.97B 25.42B 1,095B |
| Net income | 906M 813M 752M 681M 1.27B 86.34B 1.29B 8.99B 3.58B 45.18B 3.4B 3.33B 143B | 1.3B 1.17B 1.08B 978M 1.83B 124B 1.85B 12.9B 5.14B 64.85B 4.88B 4.78B 206B |
| Net Debt | -2.99B -2.68B -2.48B -2.25B -4.2B -285B -4.25B -29.66B -11.81B -149B -11.22B -10.99B -473B | -4.75B -4.26B -3.94B -3.57B -6.66B -452B -6.74B -47.07B -18.75B -237B -17.81B -17.43B -751B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | $232.40 | +2.47% | 1,943,974 |
| 27/10/26 | $226.79 | -0.38% | 1,603,484 |
| 26/10/26 | $227.66 | +1.62% | 1,436,998 |
| 23/10/26 | $224.03 | -1.43% | 1,055,960 |
| 22/10/26 | $227.28 | +0.97% | 2,212,201 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
